Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2162-3619
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy ; volume:5 ; number:1 ; day:22 ; month:6 ; year:2016 ; pages:1-11 ; date:12.2015
Experimental hematology & oncology ; 5, Heft 1 (22.6.2016), 1-11, 12.2015

Urheber
Pham, Thy
Beteiligte Personen und Organisationen
Sadowski, Martin C.
Li, Huika
Richard, Derek J.
d’Emden, Michael C.
Richard, Kerry
SpringerLink (Online service)

DOI
10.1186/s40164-016-0046-1
URN
urn:nbn:de:1111-2016062411652
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:55 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Pham, Thy
  • Sadowski, Martin C.
  • Li, Huika
  • Richard, Derek J.
  • d’Emden, Michael C.
  • Richard, Kerry
  • SpringerLink (Online service)

Ähnliche Objekte (12)

The changing landscape of hormonal therapy in castration-resistant prostate cancer

The changing landscape of hormonal therapy in castration-resistant prostate cancer

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study

Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer

Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Osteoclasts directly influence castration-resistant prostate cancer cells

Osteoclasts directly influence castration-resistant prostate cancer cells

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

Effect of simvastatin on castration-resistant prostate cancer cells

Effect of simvastatin on castration-resistant prostate cancer cells

Ureter metastatic castration-resistant prostate cancer: a case report

Ureter metastatic castration-resistant prostate cancer: a case report

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer

Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Verbundene Objekte